A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC50 = 1.4 μM) compared with sorafenib (IC50 = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC50 = 22.6 μM).
在对虚拟筛选热门化合物 N-(6-吗啉
吡啶-3-基)-2-(6-苯基
咪唑并[2,1-b]
噻唑-3-基)乙酰胺 (5a) 进行优化的基础上,设计并合成了一系列具有
咪唑并[2,1-b]
噻唑支架的新型化合物,并测试了它们对人类癌症
细胞系(包括 HepG2 和
MDA-MB-231)的细胞毒性。结果表明,化合物 2-(6-(4-
氯苯基)
咪唑并[2,1-b]
噻唑-3-基)-N-(6-(4-(4-甲氧基苄基)
哌嗪-1-基)
吡啶-3-基)乙酰胺(5l)对 V
EGFR2 的抑制率略高于 5a(5.72% 和 3.与
索拉非尼(IC50 = 5.2 μM)相比,5l 是一种潜在的
MDA-MB-231
抑制剂(IC50 = 1.4 μM),对
MDA-MB-231 的选择性高于 HepG2
细胞系(IC50 = 22.6 μM)。